Deferasirox治疗效果怎么样？

Common adverse reactions: diarrhea, vomiting, headache, abdominal pain, fever, rash, increased serum creatinine, etc. While taking Deferasirox, patients with thalassemia are often physically weak, so they should live cautiously, be comfortable with cold temperatures, and pay attention to preventing external infections; do more outdoor activities; breathe fresh air; and perform appropriate physical exercises, Qigong exercises, Tai Chi, etc. to help enhance physical fitness and disease resistance. So, how effective is Deferasirox treatment?

To explore the clinical efficacy of Deferasirox and deferoxamine in the treatment of children with severe β-thalassemia iron overload. 47 children with iron overload of β-thalassemia major were collected and divided into two groups according to different treatment plans: 26 cases in the observation group were treated with Desirox, and 21 cases in the control group were treated with deferoxamine. 

After 12 months of treatment, the therapeutic effects, serum ferritin (SF), adverse reactions, and heart and liver magnetic resonance imaging (MRI) T2 examination results of the two groups of children were compared. 

Deferasirox results: After 12 months of treatment, there was no statistically significant difference in the total effective rate between the two groups (P>0.05); the total control rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05); the heart and liver T2 values of the observation group were significantly higher than those of the control group. In the control group, the difference was statistically significant (P<0.05); after 12 months of treatment, the SF level of the observation group was significantly lower than that of the control group, the difference was statistically significant (P<0.05); the incidence of adverse reactions in the observation group was significantly lower than that of the control group, the difference was statistically significant (P<0.05).

Conclusion: The short-term effect of Desirox in treating iron overload in β-thalassemia major is significantly better than that of deferoxamine. It significantly reduces SF levels, especially the effect of iron removal in the liver, and reduces the occurrence of adverse reactions, which deserves clinical attention.

Deferasirox is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-depleting agent approved by the U.S. FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a first-line drug for patients with thalassemia iron overload over 6 years old.

Precautions when taking Deferasirox: Deferasirox may cause a rash. Generally, the rash will disappear automatically without the need to adjust the dose or stop the medication; if the condition is severe or persistent, the medication should be stopped. The patient's vision or hearing may be affected. It should be taken 30 minutes before meals. It should be taken at the same time every day. Deferasirox should not be taken with medications containing aluminum (such as stomach acid neutralizers).

The above is the content of the treatment effect, I hope it can help you!